Outcomes in patients with metastatic renal cell carcinoma who develop everolimus-related hyperglycemia and hypercholesterolemia: Combined subgroup analyses of the RECORD-1 and REACT Trials Journal Article
| Authors: | Bono, P.; Oudard, S.; Bodrogi, I.; Hutson, T. E.; Escudier, B.; Machiels, J. P.; Thompson, J. A.; Figlin, R. A.; Ravaud, A.; Basaran, M.; Porta, C.; Bracarda, S.; Brechenmacher, T.; Lin, C.; Voi, M.; Grunwald, V.; Motzer, R. J. |
| Article Title: | Outcomes in patients with metastatic renal cell carcinoma who develop everolimus-related hyperglycemia and hypercholesterolemia: Combined subgroup analyses of the RECORD-1 and REACT Trials |
| Abstract: | Micro-Abstract In this study we examined the outcome of metastatic renal cell cancer patients with everolimus treatment-related hyperglycemia and hypercholesterolemia. All patients were treated in 2 large, international prospective trials, RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) and REACT (RAD001 Expanded Access Clinical Trial in RCC). Patients who experienced these events might have experienced an improved response to everolimus. © 2016 The Author(s) |
| Keywords: | targeted therapy; mtor inhibitor; association of aes and clinical efficacy; class effects of mtor inhibition |
| Journal Title: | Clinical Genitourinary Cancer |
| Volume: | 14 |
| Issue: | 5 |
| ISSN: | 1558-7673 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2016-10-01 |
| Start Page: | 406 |
| End Page: | 414 |
| Language: | English |
| DOI: | 10.1016/j.clgc.2016.04.011 |
| PROVIDER: | scopus |
| PMCID: | PMC5063024 |
| PUBMED: | 27287020 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 6 December 2016 -- Source: Scopus |
